Sign in Subscribe
Cancer

Association Between Immunohistochemical Molecular Subtypes and Lymph Node Metastasis in Endometrial Cancer

Strategic Insights

— 1 min read

New research has shed light on the relationship between immunohistochemical molecular subtypes and lymph node metastasis in endometrial cancer. A study published in the Journal of Obstetrics and Gynaecology Research, led by Hande Nur Oncu and colleagues from the University for Health Sciences in Ankara, Turkiye, evaluated the association between molecular subtypes and lymph node metastasis in 339 patients with endometrial cancer confined to the uterus. The study found a statistically significant association between lymph node metastasis and the p53abn subtype, with 26% of patients with this subtype having lymph node metastasis compared to 17% in the MMRd group and 11% in the NSMP group.

Key Takeaways:

  • The study included 339 patients diagnosed with endometrial cancer confined to the uterus and treated with pelvic +/- para-aortic lymph node dissection (LND).
  • Patients were divided into two groups: LNM-negative (Group 1, n = 289) and LNM-positive (Group 2, n = 50).
  • The median age was 62 years (34-79) in Group 1 and 64 years (48-79) in Group 2 (p = 0.022).
  • Lymph node metastasis was detected in 14.7% of patients (50/339), with 64.4% (186/289) having a non-specific molecular profile (NSMP), 20.1% (58/289) having mismatch repair deficiency (MMRd), and 15.5% (45/289) having the p53 abnormal (p53abn) subtype.
  • A statistically significant association was observed between lymph node metastasis and the p53abn subtype (p = 0.008).
  • The study concluded that while the p53abn subtype has a significant association with lymph node metastasis, it should be considered a complementary marker alongside established clinicopathologic factors.

Statistics:

  • 339 patients were included in the study
  • 50 patients had lymph node metastasis (14.7%)
  • 289 patients had a non-specific molecular profile (NSMP)
  • 58 patients had mismatch repair deficiency (MMRd)
  • 45 patients had the p53 abnormal (p53abn) subtype
  • Median age in Group 1 was 62 years (34-79)
  • Median age in Group 2 was 64 years (48-79)

Sources:

  • Journal of Obstetrics and Gynaecology Research, 2025;51(9)
  • University for Health Sciences, Ankara Etlik City Hosp, Faculty of Medicine, Dept. of Gynecologic Oncology, Ankara, Turkiye
  • Hande Nur Oncu, Gokcen Ege, Neslihan Ozturk, Oguz Kaan Koksal, Candost Hanedan, Vakkas Korkmaz, Busra Korpe, and Caganay Soysal
  • Wiley, 111 River St, Hoboken 07030-5774, NJ, USA
  • Wiley-Blackwell - www.wiley.com/
  • Journal of Obstetrics and Gynaecology Research - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1447-0756

Read more